Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M. Source: BioSpace

With a priority review voucher in hand, Teva is expecting the FDA to rule on its new migraine treatment fremanezumab by June. Source: BioSpace

Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma. Source: BioSpace

Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades. Source: BioSpace

Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. Source: BioSpace

Shares of Agile plunged more than 62 percent in early trading after the company announced this morning the FDA rejected its low-dose hormonal contraceptive patch called Twirla. Source: BioSpace

Another lawmaker is taking on a pharmaceutical company for drug pricing. Source: BioSpace

AbbVie's investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. Source: BioSpace

Millendo Therapeutics announced that it has acquired Alize Pharma SAS in a stock-based transaction. Source: BioSpace

The parent company of JSR Life Sciences snapped up CRO Crown Bioscience International for $400M, the company announced this morning. Source: BioSpace